The study addresses a central problem in modern infectious-disease control: antibiotic resistance is not a single, uniform phenomenon. Different Salmonella lineages can acquire different resistance genes, lose them, or exchange them with unrelated bacteria. Invasive disease makes this problem especially urgent because treatment frequently begins before laboratory results are available. Clinicians may need to select an antibiotic based on local expectations, even though the infecting strain may have traveled across borders or acquired resistance in a distant setting. Genomic surveillance provides a way to see these hidden connections by comparing the DNA of bacterial isolates rather than treating every infection as an isolated event.

The researchers’ approach combines whole-genome sequencing with epidemiological and geographic analysis. Whole-genome sequencing reads the genetic material of each isolate at high resolution, allowing scientists to distinguish closely related strains and detect mutations or acquired DNA segments associated with drug resistance. Computational pipelines can identify known antimicrobial-resistance genes, changes in chromosomal targets, and mobile genetic elements such as plasmids. Plasmids are circular DNA molecules that can move between bacteria, sometimes carrying several resistance genes at once. When genomic data are linked to the date and location of sample collection, researchers can reconstruct evolutionary trees and estimate when resistant groups emerged, expanded, or moved between regions.

The analysis focuses on resistance considered a priority by the World Health Organization, a designation intended to direct attention toward threats that are difficult to treat and capable of causing substantial public-health harm. In Salmonella, resistance may compromise drugs used against invasive infections, including important classes relied upon when illness is severe. The significance of the findings lies not simply in detecting resistance genes, but in showing how they are distributed among bacterial lineages and how their prevalence changes over time. A resistance determinant found sporadically in unrelated strains suggests a different control challenge from one concentrated in a rapidly expanding international lineage.

The genomic picture indicates that resistant invasive Salmonella is being driven by multiple evolutionary processes rather than by one universal outbreak. Some resistance patterns are associated with the expansion of particular clonal groups—near-identical descendants of a common ancestor—while others appear to have been assembled through repeated horizontal gene transfer. In horizontal gene transfer, bacteria exchange genetic material directly or acquire DNA from their surroundings, enabling resistance to spread faster than ordinary reproduction alone would allow. This distinction matters for surveillance. Containing a single expanding lineage may require tracing transmission and interrupting its spread, whereas mobile resistance elements can demand broader monitoring across food systems, hospitals, communities, and animal populations.

The study’s spatial and temporal perspective is particularly important because Salmonella moves through interconnected ecological networks. Human infections can be linked to food production, livestock, poultry, wildlife, water, travel, and international trade. A strain detected in a hospital may reflect local transmission, but it may also represent an imported infection or a lineage circulating through a shared food or animal reservoir. By mapping related genomes across time and place, genomic surveillance can reveal whether resistance is emerging independently in several regions or spreading outward from established reservoirs. Such information can help public-health agencies determine where prevention should be concentrated and whether interventions are reducing transmission.

The findings also demonstrate why conventional surveillance alone can underestimate the threat. Routine monitoring often depends on phenotypic susceptibility testing, in which bacteria are grown in the presence of antibiotics to determine whether they are inhibited. This remains essential because it measures the organism’s actual response to treatment, but it may not explain how resistance is spreading. Genomic data can identify the genetic basis of resistance, uncover relationships between isolates, and detect combinations of genes that are likely to produce multidrug resistance. Conversely, genome-based prediction must be interpreted carefully: the presence of a gene does not always produce the same level of resistance, and some mechanisms remain incompletely characterized. The strongest systems therefore combine sequencing, laboratory testing, and clinical information.

For patients with invasive salmonellosis, the implications are immediate. When first-line therapy fails, bacteremia can persist and complications can become more severe, extending hospital stays and increasing the need for reserve antibiotics. The global patterns described in the study support a move toward faster, more integrated diagnostic systems capable of connecting a patient’s isolate to international databases. A genome generated within days could help identify a resistant lineage, alert clinicians to a possible treatment problem, and notify epidemiologists that apparently unrelated cases may be connected. Such systems are most useful when data are shared rapidly and consistently, with standardized methods that make results comparable across countries.

The researchers’ work ultimately presents antibiotic resistance as a moving target that must be monitored at the level of genes, lineages, populations, and ecosystems. Invasive Salmonella does not evolve in isolation, and its resistance profile can change as bacteria encounter antibiotics and exchange DNA in human, animal, and environmental settings. Global genomic surveillance cannot replace vaccination, food-safety measures, infection prevention, responsible antibiotic use, or improved access to diagnostics. It can, however, show where those measures are most urgently needed and reveal emerging threats before they become widely established. By turning scattered bacterial genomes into a dynamic map of evolution and transmission, the study offers a framework for detecting the next wave of priority resistance while there is still time to contain it.

Subject of Research: Global genomic surveillance of WHO-priority antibiotic resistance in invasive Salmonella

Article Title: Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella

Article References: Pei, Y., Yang, Z., Pang, X. et al. “Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76354-1

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76354-1

Keywords: invasive Salmonella, antibiotic resistance, antimicrobial resistance, genomic surveillance, whole-genome sequencing, WHO priority pathogens, bacterial evolution, infectious diseases, global health

The persistence of resistance to crucial antimicrobials, particularly ciprofloxacin—a cornerstone fluoroquinolone antibiotic—among Salmonella and Campylobacter strains isolated from both human cases and food-producing animals, signals a pressing clinical concern. Ciprofloxacin has long served as a frontline therapeutic agent for severe bacterial infections in humans; however, its efficacy is increasingly compromised by the widespread emergence of resistant strains. This trend is particularly alarming for Salmonella, where resistance levels in human isolates have intensified over recent years, accentuating the growing difficulty in managing salmonellosis infections effectively.

In Campylobacter spp., resistance to ciprofloxacin has become so pervasive that current clinical guidelines advise against its use for human treatment of Campylobacter infections across Europe. This development underscores the critical impact of antimicrobial applications in veterinary contexts on human health, as resistant strains originating in animal populations transit through the food chain to humans. Consequently, regulatory frameworks have tightened, restricting ciprofloxacin administration in food-producing animals as an essential stewardship measure to preserve its clinical utility.

More broadly, both Salmonella and Campylobacter isolates exhibit high resistance frequencies not only to ciprofloxacin but also to other widely deployed antimicrobials including ampicillin, tetracyclines, and sulfonamides. These agents have historically been employed extensively in veterinary and human medicine, promoting selective pressures that facilitate the persistence and dissemination of resistant bacterial populations. This resistance landscape compromises treatment efficacy and complicates infection control strategies, necessitating enhanced surveillance and judicious antimicrobial use policies.

An emerging and particularly concerning facet revealed by the report is the detection of carbapenemase-producing Escherichia coli strains in food-producing animals and meat products in several European countries. Carbapenems represent last-resort antibiotics for multidrug-resistant infections in clinical settings, and they are categorically not authorized for use in animal husbandry. The increasing identification of carbapenemase enzymes within E. coli originating from agricultural sources suggests alarming potential for horizontal gene transfer events and cross-sector dissemination, thereby elevating the risk to human health and posing a significant challenge to existing antimicrobial stewardship frameworks.

Despite these ongoing concerns, the report highlights evidence of positive trends indicative of effective intervention measures. Notably, several countries have reported substantial decreases in resistance rates in both human and animal Salmonella isolates to specific antimicrobials such as ampicillin and tetracyclines over the last decade. This phenomenon suggests that targeted, data-driven interventions—ranging from optimized antimicrobial prescribing practices to enhanced biosecurity in livestock production—can yield tangible improvements in resistance profiles at national and regional scales.

In parallel, resistance to erythromycin—a first-line therapeutic for Campylobacter infections in humans—has exhibited a downward trend in several European nations among both human and food-producing animal isolates. This favorable development signals improvements in antimicrobial management and could support more effective treatment options, thereby reducing the burden of Campylobacter-associated morbidity and potential complications.

Importantly, multidrug resistance—defined as resistance to two or more critically important antimicrobials simultaneously—remains comparatively low across Salmonella, Campylobacter, and Escherichia coli populations in Europe. This observation underscores that while resistance to individual antimicrobials persists at high levels, the emergence of extensively resistant strains has not yet reached acute proportions in many contexts, preserving some latitude for therapeutic interventions.

Nevertheless, nuanced patterns emerge within E. coli, where prior declines in antimicrobial resistance in poultry have plateaued. This stabilization rather than continued reduction in resistance levels highlights the complexity of resistance ecology and the need for sustained, adaptive strategies that address the multifactorial drivers of AMR, including antimicrobial usage intensity, farming practices, and environmental dissemination pathways.

The multifaceted nature of antimicrobial resistance reflects deeply interconnected factors spanning human clinical practices, veterinary medicine, agricultural production systems, and food safety regulatory environments. Variations observed across European countries in AMR prevalence and trends reveal disparities driven by diverse antimicrobial consumption patterns, animal husbandry methodologies, and infection prevention protocols, emphasizing the necessity for coordinated One Health strategies that integrate human, animal, and environmental health considerations holistically.

The One Health framework is critical for effectively confronting AMR in foodborne pathogens. By recognizing the bidirectional transmission potential of resistant bacteria between humans and animals through food chains, environmental reservoirs, and direct contact, integrated surveillance and intervention programs can be designed to mitigate resistance emergence and spread. This comprehensive approach necessitates harmonized data collection, risk assessment, and policy implementation across sectors to safeguard public health while supporting sustainable food systems.

Continued progress hinges on responsible antimicrobial stewardship, judicious policy enforcement, and innovation in infection prevention. Measures such as optimizing antimicrobial prescribing through evidence-based guidelines, enhancing biosecurity and husbandry conditions to reduce infection pressures, and advancing rapid diagnostic technologies are central components of a robust response. Together, these actions aim to curtail the selection and propagation of resistant strains, thereby preserving antimicrobial efficacy and ensuring effective treatment options remain available.

Importantly, public health protection requires ongoing vigilance given that AMR threatens to undermine decades of medical advancements. The progressive narrowing of effective antimicrobial arsenals due to resistance compromises not only treatment outcomes but also increases healthcare costs, hospitalization durations, and mortality risks associated with foodborne infections. This underscores the imperative for sustained investment in surveillance infrastructures, research, and cross-sector collaboration to adaptively manage the evolving AMR landscape.

The latest data encompass AMR surveillance activities conducted during 2023–2024, integrating submissions from 27 EU Member States, the United Kingdom (Northern Ireland), and five additional non-EU countries. These contributions encompass isolates from humans, food-producing animals, and meat products, representing a comprehensive One Health surveillance effort that facilitates nuanced understanding of AMR epidemiology and informs targeted public health responses across Europe.

In summary, antimicrobial resistance in pivotal foodborne pathogens remains a formidable public health challenge in Europe. Although alarming resistance levels persist, evidence of declining trends in several antimicrobial agents and bacterial species provides cautious optimism. Sustained commitment to One Health principles, underpinned by robust surveillance, responsible antimicrobial use, and enhanced infection control, is essential to curtail AMR progression and protect the effectiveness of vital antimicrobial therapies for future generations.

Subject of Research: Antimicrobial resistance in foodborne bacteria (Salmonella, Campylobacter, Escherichia coli) across Europe, focusing on surveillance data from 2023–2024.

Article Title: Widespread Antimicrobial Resistance in European Foodborne Pathogens: Challenges and Emerging Trends

News Publication Date: 2024

Web References:

• European Food Safety Authority: http://efsa.europa.eu
• European Centre for Disease Prevention and Control: http://ecdc.europa.eu
• Joint EFSA-ECDC AMR report: https://www.ecdc.europa.eu/en/publications-data/european-union-summary-report-antimicrobial-resistance-zoonotic-and-indicator-10

Keywords: Antimicrobial Resistance, Foodborne Bacteria, Salmonella, Campylobacter, Escherichia coli, Ciprofloxacin Resistance, One Health, Carbapenemase-Producing Bacteria, Antibiotic Stewardship, Public Health, Food Safety, Zoonotic Infections